基于体内治疗性基因组编辑的CRISPR/Cas的基因相关病毒载体的工程设计
Buhle Moyo1, Lucas B C Brown2, Ishika I Khondaker3
1Department of Bioengineering, Rice University, Houston, TX, 77030, USA.
Biomaterials
|April 9, 2025
概括
基因编辑CRISPR显示出对遗传疾病的希望. 腺相关病毒 (AAV) 载体在体内传递方面面临挑战,但工程策略正在改进用于临床用途的AAV-CRISPR系统.
科学领域:
- 生物技术是生物技术.
- 基因治疗 基因治疗
- 分子生物学分子生物学
背景情况:
- 美国FDA批准了首个CRISPR基因编辑疗法用于状细胞疾病和β-thalassemia,突出了CRISPR对无法治愈的遗传疾病的潜力.
- 活体基因编辑已经进步,但体内应用在高效和特定的交付方面面临重大障碍.
- 腺相关病毒 (AAV) 载体对基因传递有希望,但对体内CRISPR/Cas系统有局限性.
研究的目的:
- 审查开发体内CRISPR/Cas基因编辑疗法的挑战.
- 突出工程策略,以改善用于临床应用的AAV-CRISPR系统.
主要方法:
- 对用于基因编辑的AAV载体技术的当前文献的综述.
- 分析工程策略以提高AAV-CRISPR的效率,特异性和安全性.
主要成果:
- 在使用AAV载体实现CRISPR/Cas基因编辑机械的高效和特定的体内传递方面存在重大挑战.
- 目前正在开发各种工程策略来克服这些局限性.
结论:
- 改善AAV载体传递对于在体内推进CRISPR/Cas基因编辑疗法至关重要.
- 增强的AAV-CRISPR系统具有治疗更广泛的遗传疾病的巨大潜力.
相关概念视频
01:59CRISPR
49.8K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
49.8K
02:53CRISPR and crRNAs
16.9K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
16.9K